Raymond James reiterates Black Diamond stock rating on trial data
Raymond James reiterated an Outperform rating and $11 price target for Black Diamond Therapeutics (BDTX), citing positive Phase 2 trial data for silevertinib in non-small cell lung cancer. The stock is near its 52-week low of $1.60. The FDA has provided feedback on the Phase 3 trial design, and the company reported Q3 2026 earnings. Stifel raised its price target to $14, maintaining a Buy rating.
How this was made
The 30-second read
Why it matters
The reiteration of an Outperform rating and a $11 target suggest a near‑term bullish bias, but investors should monitor Phase 3 enrollment and regulatory milestones.
Market read
New trial data and analyst upgrade provide fresh catalyst for BDTX, potentially driving short‑term price appreciation.
What to watch
Cash runway and competition from other EGFR‑targeted therapies could temper long‑term valuation.
Background
The article summarizes analyst coverage and recent clinical trial updates for Black Diamond Therapeutics.
Ticker impact
Raymond James reiterated an Outperform rating and $11 price target after Black Diamond Therapeutics reported updated Phase 2 data showing a median progression‑free survival of 15 months and FDA feedback on a Phase 3 design.
likely upside as the market prices in the improved efficacy data and potential accelerated approval path
The new Phase 2 results and FDA alignment reduce clinical risk, prompting analysts to raise targets, which typically drives buying pressure.
Market effects
Positive data may lift sentiment across the oncology biotech sector.
U.S. biotech investors likely to react, with limited immediate impact on other regions.
Modest; primarily relevant to U.S. and global biotech investors.
Counterpoint
If the Phase 3 design faces regulatory delays, the upside could be limited despite short‑term enthusiasm.
Key entities
- analystRaymond James
Equity research firm that issued the rating and price target.
- companyBlack Diamond Therapeutics
Biotech firm developing silevertinib for EGFR non‑classical mutation NSCLC.
